Avalo Therapeutics, Inc. (AVTX)
- Previous Close
4.7300 - Open
4.6600 - Bid --
- Ask --
- Day's Range
4.5600 - 5.0788 - 52 Week Range
4.1500 - 17.4200 - Volume
46,191 - Avg. Volume
69,136 - Market Cap (intraday)
53.359M - Beta (5Y Monthly) 0.72
- PE Ratio (TTM)
-- - EPS (TTM)
-20.9100 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
31.33
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
www.avalotx.comRecent News: AVTX
View More
Performance Overview: AVTX
Trailing total returns as of 4/29/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AVTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AVTX
View MoreValuation Measures
Market Cap
53.36M
Enterprise Value
-80.62M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
84.99
Price/Book (mrq)
0.40
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-29.75%
Return on Equity (ttm)
-50.06%
Revenue (ttm)
441k
Net Income Avi to Common (ttm)
-35.13M
Diluted EPS (ttm)
-20.9100
Balance Sheet and Cash Flow
Total Cash (mrq)
134.55M
Total Debt/Equity (mrq)
0.69%
Levered Free Cash Flow (ttm)
-25.08M